drugset / Trial / NCT01967238
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
Non-randomizedSingle-groupOpen-labelBasic science
Summary
In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ improve vaccine response.
Timeline
- Start
- 2013-03
- Primary completion
- 2023-03
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Influenza Virus Vaccine | Vaccine | — | Intramuscular |
| Comparator | Pneumococcal | Vaccine | — | Intramuscular |
| Comparator | meningococcal | Vaccine | — | Intramuscular |
Indications
No indication recorded.